


PHARMACEUTICAL 2020



SOLIGENIX INC. Rank 303 of 362







PHARMACEUTICAL 2020



SOLIGENIX INC.

Rank 303 of 362

The relative strengths and weaknesses of SOLIGENIX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SOLIGENIX INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 141% points. The greatest weakness of SOLIGENIX INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 227% points.

The company's Economic Capital Ratio, given in the ranking table, is -517%, being 215% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	7,493
Cost of Goods Sold	3,567
Intangible Assets	20
Liabilities, Current	6,312
Liabilities, Non-Current	0
Other Assets	226
Other Compr. Net Income	-41
Other Expenses	-1,044
Other Liabilities	6.1
Other Net Income	141
Property and Equipment	36
Research and Development	8,123
Revenues	4,630
Selling, General and Administrative Expense	3,481

Output Variable	Value in 1000 USD
Assets	7,775
Liabilities	6,318
Expenses	14,127
Stockholders Equity	1,457
Net Income	-9,356
Comprehensive Net Income	-9,376
Economic Capital Ratio	-517%

